Generic Medicine Info
Should be taken with food.
Hypersensitivity. Blood dyscrasias (e.g. megaloblastic anaemia).
Special Precautions
Patient w/ actual or potential folate deficiency (e.g. malnourished, chronic anticonvulsant therapy, elderly). Hepatic and renal impairment. Childn (esp those w/ fragile X chromosome associated w/ mental retardation). Pregnancy and lactation. Monitoring Parameters Monitor CBC w/ differential, platelet count, liver enzyme, bilirubin, serum K, serum creatinine, and BUN periodically during prolonged therapy.
Adverse Reactions
Pruritus, rash, urticaria, mild GI disturbance (e.g. nausea, vomiting, glossitis, sore mouth); disturbance of liver enzymes, photosensitivity, angioedema, myalgia, headache; hyperkalaemia, hyponatraemia; agranulocytosis. Rarely, fever, cholestatic jaundice, exfoliative dermatitis, anaphylaxis, aseptic meningitis, megaloblastic anaemia, thrombocytopenia, leucopenia, neutropenia, methaemoglobinaemia.
Potentially Fatal: Rarely, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug Interactions
May increase concentration of dapsone. Increased elimination and shortened elimination half-life w/ rifampicin. Increases concentration of phenytoin, digoxin, procainamide, rosiglitazone, repaglinide, zidovudine, zalcitabine, lamivudine. Increased risk of nephrotoxicity w/ ciclosporin. Potentiates anticoagulant effect of warfarin. May cause hyponatraemia w/ diuretics. May cause megaloblastic anaemia w/ other folate inhibitors (e.g. pyrimethamine, methotrexate). May increase potential for bone marrow aplasia w/ bone barrow depressants. Increased risk of hyperkalaemia w/ ACE inhibitors.
CIMS Class
Other Antibiotics
ATC Classification
J01EA01 - trimethoprim ; Belongs to the class of trimethoprim and derivatives. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on trimethoprim from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in